Article
HSP90 inhibitors in lung cancer: promise still unfulfilled.
Clinical advances in hematology & oncology : H&O - 1 May 2016
Chatterjee Suman, Bhattacharya Saveri, Socinski Mark A, Burns Timothy F
Abstract excerpt
Despite recent advances in the treatment of lung cancer, non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths in the United States and worldwide, with a 5-year survival rate of less than 17%. Analysis of the molecular drivers of NSCLC led to the recognition that NSCLC is a collection of distinct, molecularly driven neoplasms. Several subsets of NSCLC with clinical relevance to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.